FREDERICK, Md., Feb. 27 /PRNewswire/ -- Vaccinogen, Inc. announced that its new vaccine to block colon cancer from recurring will be commercially available in Europe starting June 2008.
"This makes OncoVAX(R) the world's first commercially viable vaccine for colon cancer," said Dr. Michael G. Hanna, Jr., Ph.D., Chairman & CEO of Vaccinogen. "It is the beginning of our worldwide strategy of profitable distribution. Questions of the feasibility of patient specific anti-cancer therapies have been raised and this new European initiative will obviate these issues."
Pro Vaccine AG, a leading Swiss-based pharmaceutical distributor, will begin distributing OncoVAX(R) throughout Switzerland starting with Zurich and Neuchatel by June 2008. "We are very excited about the prospects of offering OncoVAX(R) to Swiss and foreign patients," said Renato Duckeck, GM of Pro Vaccine.
Pharmacenter Hungary, a rapidly growing oncology company that commercializes a broad portfolio of oncology treatments, will begin distributing the vaccine in Hungary, Czech Republic, Slovakia, Poland, Romania, Bulgaria and Slovenia starting in the third quarter of 2008. Dr. Christian Galli, Director of Business Development of Pharmacenter Hungary noted, "We recognize the excellent opportunity OncoVAX(R) provides us and the growing population of colon cancer patients in Eastern Europe."
OncoVAX(R) immunotherapy is based on a decades-long attempt by scientists to transform the body's immune response and its long-term memory to prevent the return of disease years after surgery. Such an approach has already been successful in preventing a number of infectious diseases.
Vaccinogen's scientists prepare a vaccine from the patient's own tumor and then administer the vaccine to the patient by three weekly injections one month after surgery. A fourth "booster" is administered six months later. OncoVAX(R) reduces recurrence and deaths by over 50%.
Vaccinogen is a biopharmaceutical company that develops and
commercializes cancer vaccines and other immunotherapeutic products --
Turning Cancer on Itself(TM). Based in Frederick, MD, the Company has a
portfolio of product candidates for the treatment of cancer, infectious
disease, autoimmune, anti- inflammatory diseases and fully human monoclonal
antibodies in various stages of clinical development. The Company maintains
a European subsidiary in Emmen, The Netherlands that operates a fully
functioning cGMP manufacturing center for producing OncoVAX(R) vaccines.
Andrew L. Tussing
|SOURCE Vaccinogen, Inc.|
Copyright©2008 PR Newswire.
All rights reserved